Belpointe Asset Management LLC Buys New Shares in Calidi Biotherapeutics, Inc. $CLDI

Belpointe Asset Management LLC acquired a new stake in shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 249,833 shares of the company’s stock, valued at approximately $141,000. Belpointe Asset Management LLC owned approximately 0.88% of Calidi Biotherapeutics at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Armistice Capital LLC purchased a new stake in Calidi Biotherapeutics during the first quarter valued at about $1,881,000. Millennium Management LLC lifted its stake in shares of Calidi Biotherapeutics by 35.5% in the 4th quarter. Millennium Management LLC now owns 136,137 shares of the company’s stock valued at $157,000 after acquiring an additional 35,637 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in Calidi Biotherapeutics during the 4th quarter valued at about $38,000. 12.53% of the stock is owned by institutional investors.

Calidi Biotherapeutics Stock Performance

Shares of CLDI stock opened at $1.60 on Wednesday. Calidi Biotherapeutics, Inc. has a fifty-two week low of $1.51 and a fifty-two week high of $46.68. The stock has a 50 day moving average price of $4.85 and a two-hundred day moving average price of $5.42.

Insider Buying and Selling at Calidi Biotherapeutics

In other Calidi Biotherapeutics news, CEO Eric E. Poma acquired 25,000 shares of the company’s stock in a transaction on Thursday, August 21st. The stock was acquired at an average price of $2.00 per share, for a total transaction of $50,000.00. Following the acquisition, the chief executive officer owned 25,000 shares in the company, valued at $50,000. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James A. Schoeneck acquired 75,000 shares of Calidi Biotherapeutics stock in a transaction on Thursday, August 21st. The shares were bought at an average cost of $2.00 per share, for a total transaction of $150,000.00. Following the completion of the transaction, the director owned 76,134 shares in the company, valued at approximately $152,268. This trade represents a 6,613.76% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 227,500 shares of company stock valued at $455,000 in the last 90 days. Insiders own 6.70% of the company’s stock.

Calidi Biotherapeutics Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.